Video

Treatment Options for Patients with cSCC in the Neoadjuvant Setting

Author(s):

Nikhil Khushalani, MD

An overview of treatment options for patients for with cSCC, focusing on the neoadjuvant setting.

Related Videos
Nikhil Khushalani, MD, vice chair, Department of Cutaneous Oncology, Moffitt Cancer Center
Axel Hauschild, MD, PhD, head, Skin Cancer Trial Center, University Hospital Schleswig-Holstein
Ahmad Tarhini, MD, PhD
Nivolumab plus relatlimab vs nivolumab in previously untreated metastatic or unresectable melanoma (RELATIVITY-047): overall survival and melanoma-specific survival outcomes at 3 years
Long-term follow up for adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma: Final results of the COMBI-AD study
Phase 3 study (PIVOTAL) of neoadjuvant intralesional daromun vs. immediate surgery in fully resectable melanoma with regional skin and/or nodal metastases
Zeynep Eroglu, MD
Zeynep Eroglu, MD
Zeynep Eroglu, MD
Zeynep Eroglu, MD
Related Content
Suthee Rapisuwon, MD
July 16th 2024

Adjuvant Nivolumab/Ipilimumab Lengthens DMFS in High-Risk Uveal Melanoma

Jeffrey S. Weber, MD, PhD
November 6th 2023

FDA Approval Insights: Adjuvant Nivolumab in Completely Resected Stage IIB/C Melanoma

Madan Jagasia, MD, chief executive officer of Obsidian Therapeutics
July 9th 2024

OBX-115 Earns FDA Fast Track Designation for Advanced Melanoma

Nikhil I. Khushalani, MD; Martin F. Dietrich, MD, PhD; Jason J. Luke, MD, FACP; Vishal A. Patel, MD, FAAD, FACMS
March 6th 2023

CSCC Experts Discuss Considerations for Determining Resectable Disease and Translating Data Into Practice

Recent Advances in the Evolving Treatment Landscape of Melanoma
June 14th 2024

Recent Advances in the Evolving Treatment Landscape of Melanoma

Jens Bjørheim
June 11th 2024

UV1 Cancer Vaccine as a Pembrolizumab Add-On Continues to Strengthen OS in Melanoma